RESEARCH AND DEVELOPMENT
热烈祝贺918博天堂生物在国际学术期刊Frontiers in Immunology发表了题为 “A Novel Bispecific Antibody Targeting PD-L1 and VEGF with Combined Anti-Tumor Activities”的学术论文，918博天堂CEO朱向阳博士是该论文的通讯作者。
该论文充分论述了918博天堂自主研发的全球首个靶向PD-L1/VEGF的双特异性融合蛋白HB0025卓越的CMC性能，显著的体内体外协同抗肿瘤活性和巨大的临床潜力。此研究为HB0025的临床开发提供了扎实的理论支持。HB0025已被中美两国监管机构批准进入临床，目前正在开展一项评估HB0025安全性、耐受性和初步疗效的国际多中心临床研究。
论文下载链接：http://doi.org/10.3389/fimmu.2021.778978
(A) HB0025 treatment compared with HB0023, HB002.1T, and HB0023+HB002.1T in NCG mice. (B) HB0025 treatment compared with bevacizumab, atezolizumab, and bevacizumab+atezolizumab in NCG mice. *p < 0.05, **p < 0.01, ***p < 0.001 compared with HB0025 6mg/kg.
